[Treatment of cutaneous ancylostoma larva migrans].
Caumes
E
E
Département des Maladies infectieuses et tropicales, Groupe Hospitalier, Pitié-Salpêtrière, Paris.
Gentilini
M
M
D000284:Administration, Oral; D000287:Administration, Topical; D015766:Albendazole / Q000627:therapeutic use; D000724:Ancylostomiasis / Q000188:drug therapy*; D000969:Antinematodal Agents / Q000627:therapeutic use*; D006801:Humans; D007559:Ivermectin / Q000627:therapeutic use; D007815:Larva Migrans / Q000188:drug therapy*; D008463:Mebendazole / Q000031:analogs & derivatives / Q000627:therapeutic use; D011537:Pruritus / Q000188:drug therapy; D013827:Thiabendazole / Q000008:administration & dosage / Q000627:therapeutic use
D000969:Antinematodal Agents; D007559:Ivermectin; D008463:Mebendazole; D015766:Albendazole; D013827:Thiabendazole; C018945:flubendazole
Traitement de la larva migrans cutanée ankylostomienne.